Brca Mutation News Today

Date Night actress’ mammogram and a genetic test didn’t flag her breast cancer, but a risk assessment did. So what are they, how do they work, and is having regular mammograms still important?

Kelly-Anne Phillips, MD, shares new findings suggesting that hormonal contraceptive use can increase the risk for breast cancer in those with genetic variants of BRCA1 and BRCA2.

A study in Iceland found that about 1 in 25 have variations clearly linked to a higher risk of conditions like cancer or heart disease.

Precision medicine allows a person to make specific health decisions based on a person’s own health risks.

More ovarian cancer drug approvals and treatments have become available since 2014 than in the preceding 60 years combined, emphasized Rebecca Brooks, MD, UC Davis Health.

Interim findings from the DUO-O trial could signal new options for women diagnosed with ovarian cancer at later stages who do not have a BRCA mutation.

Denver resident Jen Masket-Valenta went through a prophylactic double mastectomy last year due to her high risk of being diagnosed with breast cancer. In the wake of those two surgeries

Denver resident Jen Masket-Valenta went through a prophylactic double mastectomy last year due to her high risk of being diagnosed with breast cancer. In the wake of those two surgeries

Oliver Dorigo, MD, PhD, explains how MVP-S leverages the DPX platform to produce persistent anti-survivin immune infiltration, highlights the antitumor activity and safety observed with the combination when given to patients with recurrent ovarian cancer, and describes additional research efforts underway.

Burak Zeybeck, MD, discusses key results and clinical implications from the phase 1 NOW trial investigating neoadjuvant olaparib in patients with newly diagnosed, BRCA-mutant ovarian cancer.